Stay Updated for Free | Follow us on X

The market for monoclonal antibody therapies has grown and changed significantly, especially because of how important these therapies have been in fighting COVID-19. Even though there are still issues like virus mutations and making these treatments available to everyone, researchers are continuously working to create better and more effective therapies.

Scientists at Lawrence Livermore National Laboratory have developed a new antibody that shows promising results for fighting off different versions of the Omicron variant of the virus and it still works well against older variants like Delta.

The researchers used rapid computational methods to tweak existing antibodies to better target and fight these virus changes. By pairing data with AI/ML, potential new therapies can be quickly developed.

Computationally Designed Antibodies for Therapy

Technology Highlights

• Redesign of Monoclonal Antibody: COV2-2130 was computationally optimized to increase its neutralization potency against multiple SARS-CoV-2 variants, especially the Omicron subvariants BA.1 and BA.1.1.

• Computational Tools: Utilized high-performance computing, simulations, and machine learning for antibody redesign without experimental iterations.

• Achievements: The redesigned antibody, 2130-1-0114-112, retained the original's effectiveness against Delta and significantly improved binding and neutralization against Omicron subvariants.

Commercial Viability

• Broader Neutralization: The antibody demonstrates broad neutralization potential across several SARS-CoV-2 strains, crucial for therapeutic use against rapidly evolving viruses.

• Faster Development and Lower Costs: The computational design process allows for quicker development times and potentially lower costs compared to traditional methods, given the ability to bypass extensive iterative testing.

• Regulatory Advantage: The minor modifications from the parent antibody (COV2-2130) leverage its established clinical safety profile, potentially speeding up regulatory approval.

Challenges and Risks

• Technical Complexity: The computational redesign involves sophisticated models that require robust computational resources.

• Regulatory Hurdles: Despite reduced testing due to leveraging previous data, the novel designs must meet stringent regulatory standards.

• Market Adoption: Dependence on the healthcare sector's readiness to adopt computationally designed antibodies, which may vary by region and specific medical standards.

Market Analysis

COVID-19 Monoclonal Antibody Therapy Market

The COVID-19 pandemic really accelerated the development and use of monoclonal antibody therapies as a key treatment option. These therapies, designed to neutralize the SARS-CoV-2 virus, have received emergency use authorization in many countries. This makes them a major part of the overall market for monoclonal antibody (mAb) therapeutics.

Trends [1][2][3]:

• The use of monoclonal antibodies (mAbs) in treating COVID-19 has varied due to the emergence of new virus variants.

• Initially, treatments such as bamlanivimab, casirivimab/imdevimab, and sotrovimab were widely used.

• As different virus variants appeared, the effectiveness of these therapies changed, leading to adjustments in their use.

Segments [4]:

• The COVID-19 monoclonal antibody market is categorized into different segments:

  • Type of therapy: single drug vs. cocktail

  • Route of administration: IV infusion vs. subcutaneous injection

  • Specific drugs used

• The choice of therapy often depends on the prevalent virus variant, the patient's health condition, and other medical considerations.

Challenges [3]:

• A major challenge is the rapid mutation of the virus, which can make existing treatments less effective.

• Logistical issues in delivering these treatments and their high costs have also limited their accessibility and use.

Opportunities [3]:

• Continuous research and development are focused on creating new, more effective mAbs that can target a broader range of SARS-CoV-2 variants.

• Efforts are also being made to develop therapies that can be used preventively, especially in immunocompromised individuals, potentially expanding the market.

Broader Applications of Monoclonal Antibody Therapies

Market Size and Growth [5]:

• The monoclonal antibody therapeutics market, not just limited to COVID-19, is both large and expanding quickly.

• In 2024, the market was estimated at $252.6 billion, with expectations to grow to $497.5 billion by 2029. This represents a growth rate (CAGR) of 14.5%.

• This growth is spurred by the rising number of chronic diseases, autoimmune disorders, and infectious diseases, as well as advancements in the technology used for antibody engineering and production.

Key Segments and Drivers:

• Therapeutic Areas:

  • Monoclonal antibodies (mAbs) are used across various therapeutic areas, such as oncology, autoimmune diseases, and infectious diseases.

  • Notable drugs like rituximab, used for lymphoma and leukemia, and trastuzumab, used for breast cancer, highlight the success of mAbs in these fields.

• Production Methods and End Users:

  • The market is segmented by production methods (e.g., in-vitro) and the types of end users (hospitals, long-term care facilities).

  • In 2023, hospitals were the largest segment of the mAb therapeutics market, driven by increased patient admissions and healthcare infrastructure improvements.

The market for monoclonal antibody therapies has seen significant growth, particularly in combating COVID-19. Despite challenges like virus mutations and accessibility, ongoing research promises better treatments. Beyond COVID-19, advancements in technology and the rise in chronic and autoimmune diseases are driving market expansion, signaling a bright future for these therapies.

Research at Lawrence Livermore National Laboratory highlights how designing antibodies using computers can help us tackle current issues in treating infectious diseases. This method gives us a quick and strategic advantage in responding to new pathogens.

Original Technology Publication